- Home
- RAPT
RAPT
RAPT Therapeutics Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2019 |
| Target Price: | $5.00 | AVG Volume (30 days): | 922.1K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.79 - $9.65 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
23 days ago
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Clinical Trials Arena
a month ago
Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer
Zacks
2 months ago
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
GlobeNewswire
3 months ago
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
3 months ago
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
TipRanks
3 months ago
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
MT Newswires
3 months ago
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade
Compare RAPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPT RAPT Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.